It was shown that either COX-2 specific inhibitor Celecoxib or non-selective COX-2 inhibitor Sulindac synergizes with decitabine to inhibit GC in in vitro and in vivo, suggesting that targeting PGE2-DNMT axis represents a novel approach that may be used in prevention and treatment of GC. Here, PTGS2 is linked to gastric cancer.